AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced solid tumors or lymphoma * Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field * Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator * No untreated or symptomatic brain metastases * No tumors with direct bowel invasion * No other hematological malignancies * No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum) PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Not pregnant * No nursing during and for 6 months after completion of study treatment * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * Negative pregnancy test * Able to swallow oral medication * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL * Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min * Albumin-adjusted calcium ≥ 8 mg/dL * Urine protein \< 30 mg/dL by urinalysis or \< 1+ by dipstick OR \< 500 mg by 24-hour urine collection * AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm) * Bilirubin ≤ 2 times ULN * PT ≤ 2.0 * INR or PTT ≤ 1.5 times ULN * Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed) * No myocardial infraction within the past year * No arterial thrombosis or deep vein thrombosis within the past year * No unstable angina * No congestive heart failure * No New York Heart Association class III-IV cardiac disease * No other unstable or uncontrolled disease or condition relating to or impacting cardiac function * No HIV positivity * No other condition that would preclude study participation, compliance, or follow-up assessments PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior enrollment into this study * At least 1 month since prior investigational device or drug trial * At least 1 month since prior major surgical procedure * At least 3 weeks since prior systemic chemotherapy * At least 2 weeks since prior radiotherapy * At least 2 weeks since prior rifampin or phenobarbital * At least 1 week since prior treatment with any of the following: * Ketoconazole * Itraconazole * Clarithromycin * Erythromycin * Cyclosporine or tacrolimus * Nefazodone * Herbal medications containing Hypericum perforatum (St. John's wort) * At least 1 week since prior and no concurrent warfarin * Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin \[≤ 2 mg/day\] or low molecular weight heparin) for venous or arterial access devices allowed * No prior or concurrent kinase insert domain-receptor inhibitors * No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy * Gonadotropin releasing-hormone agonist therapy allowed * No concurrent interferon * No concurrent grapefruit juice or whole grapefruit * No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors * No elective surgery during or for 2 weeks after completion of the last dose of AMG 706